In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties
about
SB 206553, a putative 5-HT2C inverse agonist, attenuates methamphetamine-seeking in ratsThe 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivoRS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonistSerotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cellsPharmacology of serotonin and female sexual behaviorReciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agentsRNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoformsModulation of dopamine release by striatal 5-HT2C receptorsSB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissueInfluence of the 5-HT(2C) receptor antagonist SB242,084 on behaviour produced by the 5-HT(2) agonist Ro60-0175 and the indirect 5-HT agonist dexfenfluramineFunctional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptorsPreferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis studySimilarities between the Binding Sites of SB-206553 at Serotonin Type 2 and Alpha7 Acetylcholine Nicotinic Receptors: Rationale for Its Polypharmacological ProfileRegion-dependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin2C receptorsAn immunocapture/scintillation proximity analysis of G alpha q/11 activation by native serotonin (5-HT)2A receptors in rat cortex: blockade by clozapine and mirtazapineGenetic variation in cortico-amygdala serotonin function and risk for stress-related diseasePharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors.SB242084, flumazenil, and CRA1000 block ethanol withdrawal-induced anxiety in ratsMirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.Strain-dependent effects of diazepam and the 5-HT2B/2C receptor antagonist SB 206553 in spontaneously hypertensive and Lewis rats tested in the elevated plus-maze.Expression and function of serotonin 2A and 2B receptors in the mammalian respiratory networkIn vivo evidence that 5-HT2C receptor antagonist but not agonist modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatum.Locomotion after spinal cord injury depends on constitutive activity in serotonin receptorsBinding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907.Opposing effects of 5-HT(2A) and 5-HT(2C) receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test.S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat.In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist.Citalopram-induced hypophagia is enhanced by blockade of 5-HT(1A) receptors: role of 5-HT(2C) receptors.Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats.Activation of lumbosacral 5-HT2C receptors induces bursts of rhythmic activity in sympathetic nerves to the vas deferens in male rats.Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory.Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictionsMultiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.Targeting brain α7 nicotinic acetylcholine receptors in Alzheimer's disease: rationale and current status.A review of animal models of obsessive-compulsive disorder: a focus on developmental, immune, endocrine and behavioral models.Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).1,3-diphenylpropan-1-ones as allosteric modulators of α7 nACh receptors with analgesic and antioxidant properties.The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors.
P2860
Q21262960-2115BE02-9439-46C2-97D2-8D9AEFFDD136Q24671423-BBA819D8-8F06-464B-A8FF-EC98862452DCQ24672108-E1028392-B0F2-4988-A36A-D8CD0508EE43Q24685016-4F3BCD32-9EA2-4EEC-98DC-1F25BA1D40CBQ26861672-7F426ED2-AA63-4E74-9C60-3440DE43D586Q28140526-1076582F-A0B8-49B2-AF04-D258EB0FE569Q28182190-2D5341E3-5DB6-4C0E-B38C-83F4E905FA76Q28304071-7FBD7022-2481-4301-863D-73AF559213C4Q28343900-02288256-143F-46CA-9E6B-D9A7E58CFA06Q28366550-4B054BF2-B990-4893-8EA2-2B5D1F07D6CBQ28369500-A35FC49F-290D-41BB-8D68-17A070F15CF3Q28377153-9B963015-9863-4AC3-A67B-7E3E85AFD5D1Q28547013-A2F0A18C-C6AE-41F4-8521-7CDF348AC4A1Q28570213-12DBA730-45F3-4D36-812D-60773CE8088EQ28578911-E9389FFE-9519-4F2B-8115-B5D0E92660CCQ30487278-DD963944-64ED-4760-A5F7-F7B51EAB2DDCQ30493133-4686B189-3350-49A5-98C4-70DB45703609Q30500846-B4BC3704-DA13-4EB1-8DBB-65A6729254B9Q33856044-3ACB1E19-0366-4BD2-B9A2-6366DE93F194Q33897936-CE26F5B1-F5B1-4A79-9FC3-D4FFD4B52814Q33944317-F440BB1F-8ADB-46E1-AF7B-83622C433596Q33971067-0C722E5F-4EBE-4D44-A30C-4A91746D34A5Q34270096-300E5FA2-A1BF-4504-9D9C-5FF4FE94ED71Q34430446-5687B19F-8A0B-42F1-BDD1-D54B94861361Q34457050-BD9DAFDB-6678-4D31-9191-3E111BE265F3Q34659207-06348132-AA4B-40D0-9093-D031645982F7Q34784727-DD0F7EEB-5F4D-485D-A512-19A9F1559FF1Q34791678-3E7CF41D-3DA4-4897-A46F-EC4B5B58E74CQ34999100-DBF84A8F-17BC-4551-A5AE-9EBC93AF3CC5Q35027938-DDD253DD-31E4-4653-9732-31EC82C9A55DQ35029076-3576AFE1-56F7-4396-B282-01A0A1AB18D9Q35546420-FA7E7002-1A28-46E8-9CF6-3072935D41EDQ35686715-5C9BC58F-2D59-4B67-B082-C675EC48E2D1Q37104004-E74BB180-97D9-4F7F-9C65-6994348B439AQ38101499-27A3F4E8-916C-4ACA-A342-E1138F60C145Q38253573-82B21C7C-D94F-452E-9697-8846CB908226Q38630519-EF92F389-0490-4187-9710-45EB6582A020Q38648544-2DDA9FC6-34A9-4876-A65A-EA4A542CEE2DQ38869450-3015FD85-9FAB-44A1-84D2-611B63F76557Q38934855-17935C73-B187-40F7-B58A-A6C099DAD714
P2860
In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties
description
1996 nî lūn-bûn
@nan
1996 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
In vitro and in vivo profile o ...... ith anxiolytic-like properties
@ast
In vitro and in vivo profile o ...... ith anxiolytic-like properties
@en
In vitro and in vivo profile o ...... ith anxiolytic-like properties
@nl
type
label
In vitro and in vivo profile o ...... ith anxiolytic-like properties
@ast
In vitro and in vivo profile o ...... ith anxiolytic-like properties
@en
In vitro and in vivo profile o ...... ith anxiolytic-like properties
@nl
prefLabel
In vitro and in vivo profile o ...... ith anxiolytic-like properties
@ast
In vitro and in vivo profile o ...... ith anxiolytic-like properties
@en
In vitro and in vivo profile o ...... ith anxiolytic-like properties
@nl
P2093
P2860
P1476
In vitro and in vivo profile o ...... ith anxiolytic-like properties
@en
P2093
G A Kennett
G S Baxter
I T Forbes
P2860
P304
P356
10.1111/J.1476-5381.1996.TB15208.X
P407
P577
1996-02-01T00:00:00Z